Trial Profile
A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs PF 5212366 (Primary)
- Indications Meningococcal meningitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer; Wyeth
- 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
- 11 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.